Gland Pharma Limited
4,601words
3turns
0analyst exchanges
0executives
Key numbers — 40 extracted
rs
25
7%
12%
8%
18%
65%
60%
66%
39%
24%
19%
25%
Guidance — 17 items
Corporate Office
opening
“5 5 Base Business (Gland) P&L Highlights Base Business (Gland) P&L Highlights * Particulars Particulars Q1 FY26 Q1 FY26 Q1 FY25 Q1 FY25 YoY YoY Q4 FY25 Q4 FY25 Revenue from operations Revenue from operations Other Income Other Income Total Income Total Income (1) Gross Profit(1) Gross Profit Gross Profit margin (%) Gross Profit margin (%) EBITDA(2) EBITDA(2) EBITDA margin(%)(3) EBITDA margin(%)(3) Adj.EBITDA(4) Adj.EBITDA(4) Adj.”
Corporate Office
opening
“Mn) 10,134 10,134 10,332 10,332 10,409 10,409 Gross Profit (1) / Gross Profit Margin (2) / Gross Profit Margin & Gross Profit (< Mn / %) (₹ Mn / %) 5,348 5,348 53% 53% 6,280 6,280 61% 61% 6,144 6,144 59% 59% Q1 FY25 Q1 FY25 Q4 FY25 Q4 FY25 Q1 FY26 Q1 FY26 Q1 FY25 Q1 FY25 Q4 FY25 Q4 FY25 Q1 FY26 Q1 FY26 EBITDA / EBITDA Margin <3>/ PAT / PAT Margin W EBITDA / EBITDA Margin (3) / PAT / PAT Margin (4) (₹ Mn / %) (?”
Corporate Office
opening
“Mn / %) 2,941 2,941 29% 29% 2,248 2,248 22% 22% 3,954 3,954 38% 38% 2,913 2,913 28% 28% 3,592 3,592 35% 35% 2,692 2,692 26% 26% 489 489 4.8% 4.8% 503 503 4.9% 4.9% 460 460 4.4% 4.4% Q1 FY25 Q1 FY25 Q4 FY25 Q4 FY25 Q1 FY26 Q1 FY26 Q1 FY25 Q1 FY25 Q4 FY25 Q4 FY25 Q1 FY26 Q1 FY26 EBITDA EBITDA ■ PAT PAT 1.Gross Profit = Revenue from Operations – Materials consumed 2.”
Corporate Office
opening
“Mn) (₹ Mn) 87,238 87,238 91,507 91,507 95,587 95,587 ROCE (2) / RONW (3) ROCE (2) / RONW (3> (%) (%) RoCE RoCE RoNW RoNW 11% 11% 9% 9% 9% 9% 8% 8% 11% 11% 9% 9% 15.00% 10.00% 5.00% 0.00% FY24 FY24 FY25 FY25 Jun'25 Jun'25 FY24 FY24 FY25 FY25 Jun'25 Jun'25 Capital Expenditure Capital Expenditure (₹ Mn) (?”
Corporate Office
opening
“Mn) (₹ Mn) 4,277 4,277 18,394 18,394 15,197 15,197 25,562 25,562 22,870 26,179 26,179 23,009 23,009 3,259 2,620 2,620 FY24 FY24 FY25 FY25 Jun'25 Jun'25 Q1 FY25 Q1 FY25 Q4 FY25 Q4 FY25 Q1 FY26 Q1 FY26 Net Working Capital (2) Net Working Capital (2) (?”
Corporate Office
opening
“Mn) (₹ Mn) 21,554 21,554 21,683 21,683 22,853 22,853 Cash Conversion Cycle (CCC) (3)(4) Cash Conversion Cycle (CCC) (3)(4) (# of Days) (# of Days) 173 173 152 152 78 78 -57 -57 FY24 FY24 172 172 138 138 100 100 -66 -66 FY25 FY25 161 161 135 135 95 95 -69 Jun'25 Jun'25 FY24 FY24 FY25 FY25 Jun'25 Jun'25 Receivable days Receivable days Inventory days Inventory days Payable days Payable days Cash conversion cycle Cash conversion cycle 9 9 1.”
Corporate Office
opening
“GLAND Business Update Business Update Base Business (Gland) Updates Base Business (Gland) Updates (cid:127) R&D Expenses: Total R&D expenses were ?460 million in Q1 FY26, representing 4.4% of revenue.”
Corporate Office
opening
“• R&D Expenses: Total R&D expenses were ₹460 million in Q1 FY26, representing 4.4% of revenue.”
Corporate Office
opening
“• (cid:127) (cid:127) • Filings and Approvals: One ANDA was filed and nine were approved in Q1 FY26, contributing to a cumulative total of 372 ANDA Filings and Approvals: One ANDA was filed and nine were approved in Q1 FY26, contributing to a cumulative total of 372 ANDA filings in the U.S.”
Corporate Office
opening
“• Co-development Partnerships: Fifteen products are in co-development (seven 505(b)(2) and eight ANDAs), with commercialization (cid:127) Co-development Partnerships: Fifteen products are in co-development (seven 505(b)(2) and eight ANDAs), with commercialization anticipated to begin in FY28.”
Advertisement
Speaking time
1
1
1
Opening remarks
Regd. Office
Survey No. 143-148, 150 & 151, Near Gandimaisamma ‘X’ Roads D.P. Pally, Dundigal, Dundigal-Gandimaisamma Mandal Medchal-Malkajgiri District, Hyderabad 500043,Telangana, India Tel: +91-40-30510999 Fax: +91-40-30510800
Corporate Office
Plot No. 11 & 84, TSIIC Phase: IV Pashamylaram (V), Patancheru (M), Sangareddy District Hyderabad 502307, Telangana, India Tel: +91-8455-699999 CIN: L24239TG1978PLC002276 | email: gland@glandpharma.com; investors@glandpharma.com | www.glandpharma.com GLANDI GLAND PHARMA GLAND PHARMA Investor Investor Presentation Presentation Q1FY26 Q1FY26 05 August 2025 05 August 2025 Safe Harbour Statement Safe Harbour Statement The Presentation is to provide the general background information about the The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any investor estimates and should not be considered as a recommendation that a
Investor Relations
Sampath Kumar Pallerlamudi Sampath Kumar Pallerlamudi Company Secretary & Compliance Officer Company Secretary & Compliance Officer Shriniwas P. Dange Shriniwas P. Dange Investor Relations Investor Relations investors@glandpharma.com investors@glandpharma.com Corporate Office Corporate Office Gland Pharma Limited Gland Pharma Limited Plot No. 11 & 84, TSIIC Phase: IV Plot No. 11 & 84, TSIIC Phase: IV Pashamylaram (V), Patancheru (M), Pashamylaram (V), Patancheru (M), Sangareddy District Sangareddy District Hyderabad 502307, Telangana, India Hyderabad 502307, Telangana, India 3 S E 543245 543245 0 NSE GLAND GLAND Bloomberg GLAND:IN 3LANDJN 19 19
Advertisement